Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mt-6402
- Development stage
- Discontinued
- Lead developer
- Molecular Templates
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
MT-6402 is a third-generation engineered toxin body (ETB) developed by Molecular Templates. It is designed to target and eliminate PD-L1-expressing tumor and immune cells in patients with advanced solid tumors, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The drug consists of an immunoglobulin fragment that binds PD-L1 fused to a de-immunized Shiga-like toxin A subunit (SLTA), which irreversibly inhibits ribosomal function upon internalization, leading to direct cytotoxicity. Additionally, MT-6402 delivers an HLA-A*02-restricted cytomegalovirus (CMV) class I antigen into PD-L1+ cells ("antigen seeding"), enabling recognition by CMV-specific cytotoxic T cells. Its mechanisms include direct tumor cell kill, depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), remodeling the tumor microenvironment to restore T-cell surveillance, and enhancing immune recognition through antigen seeding[1][2][5][8].
- Other names
- ADC PDL1 - Toxin - Molecular Templates
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on mt-6402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mt-6402.